MARKET

EVLO

EVLO

Evelo Biosciences
NASDAQ
1.040
+0.020
+1.96%
Closed 16:30 01/31 EST
OPEN
1.050
PREV CLOSE
1.020
HIGH
1.050
LOW
1.030
VOLUME
40.19K
TURNOVER
--
52 WEEK HIGH
5.29
52 WEEK LOW
0.9400
MARKET CAP
114.00M
P/E (TTM)
-0.5847
1D
5D
1M
3M
1Y
5Y
BRIEF-Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update
Reuters · 01/11 22:07
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 12/21/2022 18:51
BRIEF-Evelo Biosciences Announces $45 Million Loan Agreement With Horizon Technology Finance Corporation To Refinance Existing Debt
Reuters · 12/16/2022 11:16
Evelo Biosciences, Inc. (NASDAQ:EVLO) insiders placed bullish bets worth US$575k in the last 12 months
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Simply Wall St. · 12/01/2022 12:40
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Benzinga · 11/16/2022 15:06
Chardan Capital Downgrades Evelo Biosciences to Neutral, Announces $2.5 Price Target
Benzinga · 11/16/2022 13:27
--Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5
--Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5
MT Newswires · 11/16/2022 08:06
Evelo Biosciences Announces Publication Of Scientific Basis For SINTAX Medicines In Frontiers In Immunology
Benzinga · 11/15/2022 21:01
More
About EVLO
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing an orally delivered investigational medicines that acts on cells in the small intestine to produce therapeutic effects throughout the body. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are orally delivered pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles. Its product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Its other product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease. It has developed an integrated platform namely, SINTAX Medicine Platform, which is designed to identify individual strains of microbes capable of modulating the immune system by acting on SINTAX when administered at pharmacologically active doses and appropriately formulated.

Webull offers kinds of Evelo Biosciences Inc stock information, including NASDAQ:EVLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVLO stock methods without spending real money on the virtual paper trading platform.